Regent Pacific Group Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RPGLF research report →
Companywww.endurancerp.com
Regent Pacific Group Limited, an investment holding company, holds investments in the healthcare and life sciences sectors in Europe and Taiwan. The company operates in two segments, Biopharma and Corporate Investment. It engages in the research, development, manufacture, marketing, and sale of pharmaceutical products for the treatment and management of urological disorders; and development of artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels.
- CEO
- Jamie Alexander Gibson
- IPO
- 1997
- Employees
- 13
- HQ
- Central, HK
Price Chart
Valuation
- Market Cap
- $1.72M
- P/E
- -5.55
- P/S
- 71.85
- P/B
- -3.93
- EV/EBITDA
- -6.96
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -115.70%
- Op Margin
- -1187.88%
- Net Margin
- -1297.52%
- ROE
- 87.15%
- ROIC
- -755.27%
Growth & Income
- Revenue
- $348.51K · -51.53%
- Net Income
- $-4,716,967 · -5.24%
- EPS
- $-0.02 · 8.16%
- Op Income
- $-4,318,378
- FCF YoY
- -4.11%
Performance & Tape
- 52W High
- $0.43
- 52W Low
- $0.00
- 50D MA
- $0.02
- 200D MA
- $0.10
- Beta
- 1.19
- Avg Volume
- 2
Get TickerSpark's AI analysis on RPGLF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our RPGLF Coverage
We haven't published any research on RPGLF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RPGLF Report →